Welcome to KAHR Medical
The mission at KAHR Medical is to develop novel fusion protein pharmaceuticals
for the treatment of cancer and autoimmune diseases.
KAHR's drug development pipeline is built around 'Dual Signaling Proteins (DSP)'
- a unique class of novel therapeutic agents that possess two functional ends.
The DSP technology is divided into two proprietary platforms; the DSP-Hexamers and the
DSP-Clusters, each covering hundreds of drug candidates. KAHR actively operates two
drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept
for its two proprietary platforms.
News & Events
February 15, 2016: KAHR Medical Completes a $15M Series B Private Equity Financing
December 12, 2015: KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing
December 6, 2015: KAHR Medical presents KAHR-102 pre-clinical data at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, FL.
December 1, 2015: KAHR obtains regulatory approval to start a Phase-I/IIa clinical trial with KAHR-102 in lymphoma patients. Trial to start in Israel in mid 2016.
October 13, 2015: KAHR obtains final reports of toxicology studies for KAHR-102. Studies show KAHR-102 is well tolerated in mice and monkeys.
August 22, 2015: Prof. Arnold Freedman from Harvard Medical School joins KAHR's Scientific Advisory Board. Professor Freedman is the Clinical Director of the Lymphoma Program at the Dana-Farber Cancer Institute and a leading expert on lymphoma drug clinical development
June 28, 2015: KAHR Medical submits IND-equivalent file to Israeli regulatory authorities to study KAHR-102 in lymphoma patients as part of a Phase-I/IIa clinical trial